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Abstract
Identification of cancer cells in the lymph nodes surrounding a tumor is important in establishing
prognosis. Optical detection techniques such as fluorescence and photoacoustic tomography
(PAT) have been reported in preclinical studies for noninvasive sentinel lymph node (SLN)
mapping. A method for validation of these techniques is needed for clinical trials. We report the
use of a multimodal optical-radionuclear contrast agent as a validation tool for PAT in a
preclinical model. Methylene blue (MB) was radiolabeled with 125I for multimodal SLN mapping
and used in conjunction with MB to assess the feasibility of multimodal SLN mapping in a rat
model by PAT and SPECT. MB provided sufficient contrast for identifying SLNs non-invasively
with a PAT system adapted from a clinical ultrasound imaging system. The signal location was
corroborated by SPECT using 125I labeled MB. The translation of PAT into the clinic can be
facilitated by direct comparison with established imaging methods using a clinically relevant dual
SPECT and photoacoustic imaging agent. The new high resolution PAT is a promising technology
for sensitive and accurate SLN detection in cancer patients.
Introduction
Until recently, radical lymph node resection with ex vivo histopathology was routine for
staging cancers including breast and prostate cancers. This procedure often resulted in
significant morbidity from local fluid retention and consequent infection, pain and limited
limb use 1 and is no longer considered the standard of care 2. Selective biopsy of lymph
nodes that are first encountered by metastatic cells is a less traumatic diagnostic method and
has been found to be more useful for staging without impacting treatment in most cases. In
cancer staging, detection of tumors in the sentinel lymph nodes (SLNs), which are the first
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nodes that drain the area of interest, is an important prognostic factor that directs treatment
planning. Lymphoscintigraphy for SLN mapping was introduced in 1977 using radiolabeled
colloidal gold 3. Tracer agents were selected by the rate of uptake in the lymph nodes and
limited diffusion outside of the lymphatic system 4. SLNs can be detected by regional
subcutaneous injection of contrast agents. For example, 99mTc sulfur colloid is widely used
pre-operatively and intraoperatively to detect SLNs 5.
SLN mapping is complex due to the variety of drainage pathways from the primary tumor
site 6. The detection of lymph nodes and distinction of SLNs may be complicated by the
choice of contrast agent and by lymphatic channels temporarily accumulating contrast
agents that can be mistaken as lymph nodes 7. Thus, 3D nuclear imaging methods such as
SPECT are useful for noninvasive localization of the SLN. Hybrid SPECT/CT instruments
are now available and provide the ability to determine the exact anatomical location of SLNs
and improve lymphatic mapping 8.
To aid intraoperative visualization of the lymph drainage into SLNs, vital dyes are
commonly employed. One of the dyes used to guide SLN biopsy in humans is methylene
blue (MB). SLN localization using vital dyes alone is limited to wide-field exposure of the
peritumoral area for visualization of the distinct blue color with unaided human eye 9. This
approach is not efficient because of the need to use large amounts of the dye, which can only
be visualized invasively. This limitation of detection has led several groups to postulate that
radioisotopes are superior to dye contrast agents for identifying SLNs in cancer
patients 10, 11.
Recent studies, however, have shown that a new hybrid imaging method known as
photoacoustic tomography (PAT) may alter the existing paradigm of SLN mapping. PAT
combines the sensitivity of optical imaging with the spatial resolution of ultrasound. This
imaging technology is capable of detecting light-absorbing compounds several centimeters
below the skin surface 12. The sensitivity of PAT to contrast agents is much greater than
ultrasound 13 and the ability of PAT to interrogate deep tissue noninvasively allows its use
for 3D imaging and non-invasive lymph node identification for SLN biopsy. The success of
this technology in small animal imaging has motivated current efforts to translate it into the
clinical arena 14. A primary focus of these efforts is the validation of PAT as a viable
method for imaging SLN in human patients. Since PAT does not use ionizing radiation, it is
amenable to use in surgical suites. However, there is an urgent need to validate this new
technology with an established imaging method. Considering the important role of SPECT
in SLN mapping, one strategy to validate PAT is to use a common contrast agent for both
PAT and a more established imaging modality such as SPECT. Here, we report our initial
efforts in multimodal imaging with MB and 125I-MB for validating PAT of SLN with
SPECT/CT.
Methods
Radiolabeling
Methylene blue (MB, Sigma, St. Louis, MO) was radiolabeled with 125I sodium iodide
(American Radiolabeled Chemicals, Inc. St. Louis, MO, USA) as previously
described 15. 125I-NaI (37MBq) was added to freshly prepared potassium iodide/iodate
solution (585 µg KI and 3.85 mg KIO3). The mixture was acidified (0.25 ml, 0.18 M HCl)
and heated (60 min, 100°C.) Reaction progress was monitored by reversed phase, radio-
HPLC (Altima, C18, 3 µm, 7 mm × 53 mm, 2.5 mL/min, A=0.1% TFA, water, B=0.1%
TFA, acetonitrile, 30–90% B, 10 m).
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In vivo Imaging
All animal studies were conducted according to guidelines on the humane care and use of
laboratory animals under protocols approved by the Animal Studies Committee at
Washington University School of Medicine.
A combined hand-held PAT and ultrasound (US) imaging system adapted from a clinical US
array system (iU22, Philips Healthcare) was used for in vivo mapping of lymph nodes in
rats 14. An optically tunable dye laser (PrecisionScan-P, Sirah), pumped by a Q-switched
Nd:YAG laser (PRO-350-10, Newport), produced pulsed lasers with a duration of 6.5 ns at a
repetition rate of 10 Hz. The light was coupled to bifurcated fiber bundles (CB18043,
Fiberguide), which were integrated with a hand-held US array probe (L8-4, Philips
Healthcare). An optical wavelength of 650 nm, close to the peak optical absorption
wavelength of methylene blue (667 nm), was utilized. Light fluence on the surface was ~3
mJ/cm2, only 1/7 of the ANSI safety limit (20 mJ/cm2) 16. Generated PAT waves were
detected by the linear array US probe with a nominal bandwidth of 4–8 MHz. PAT images
were displayed at ~1 frame per second (fps). The imaging depth was increased by layering
~2-cm thick chicken tissue on top of the rat to demonstrate the deep-imaging capabilities of
PAT at clinically relevant depths. MB (0.1 ml of 1%) was injected in the left front forepaw
of 200–250 g female Sprague Dawley rats (HSD, Indianapolis, IN) (n=3), and in vivo PAT
imaging was performed. Co-registered PAT and US images identify MB-enhanced SLNs
(from PAT) in ratsand the surrounding anatomical structures (from US imaging).
For multimodal imaging, 125I-MB (~200 µCi) was added to 1% MB (0.1 ml, PBS). An
aliquot of 0.1 ml was drawn into a 0.5 ml insulin syringe and activity measured with dose
calibrator before injecting subcutaneously in the left forepaw as for PAT (n=3). The activity
remaining in the syringe was measured and injected dose calculated. SPECT/CT imaging
was performed immediately after injection of 125I-MB and at 1 h after injection with the
NanoSPECT/CT preclinical imaging system (Bioscan, Inc., Washington, D.C.). Scanning
regions were selected by side-view topogram, extending from the xyphoid to the base of the
jaw. CT was performed on a 45 KVP, 177 mA and 180 400 ms projections helical CT with
pitch of 1. The CT scan was followed by helical SPECT with 16 projections and 60 seconds
each. Energy windows were set to 28 KeV and 30% width. CT and SPECT projections were
reconstructed using InvivoScope software (Bioscan, Inc.).
After SPECT/CT imaging, planar scintigraphy was performed using the IS4000MM
multimodal imaging system (Carestream Health, New Haven, CT). White light,
fluorescence, X-ray and scintigraphy images were acquired. Following SPECT/CT, the rats
were euthanized with pentobarbital solution (150 mg/kg, IP). The skin overlying the axillary
region was removed for visualization of the axillary lymph nodes. Planar scintigraphy was
performed and color images acquired with digital camera. The lymph nodes were resected
and images acquired for comparison of contralateral, control lymph nodes to confirm 125I-
MB uptake in lymph nodes using the optical imaging and planar scintigraphy. Activity in the
lymph nodes was measured using the dose calibrator and percent injected dose per gram
tissue (%ID/g) calculated.
Results
Initial attempts to prepare iodo-methylene blue using the standard iodogen method resulted
in the appearance of a major impurity that was not further characterized. To overcome this
problem, we utilized KI/KIO3 under acidic conditions instead of the iodogen method 15.
Purification of the mixture yielded 125I –MB 17 (Figure 1), which has a retention time of
4.86 min and 97% purity based on the peak area. The unlabeled methylene blue eluted
approximately 2 minutes before the iodinated species. A minor component that eluted at
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4.95 min was the putative di-iodinated species that has been previously described 15.
Incorporation of 125I in I-MB was quantitative and complete in 10 minutes. Because specific
activity was not an issue in this study, the isolated 125I-MB was not further purified.
PAT images show clearly localized lymph nodes containing blue dye (Figure 2). A control
PAT image was acquired before injection of MB (Figure 2A). Soon after injection, MB
accumulation in the SLN was detected photoacoustically. Figure 2B shows the PAT image
of the MB-dyed SLN acquired at 10 min post-injection. An overlaid PAT and US image
(Figure 2C) provides both functional (MB uptake in the SLN) and structural information.
Post-mortem photographs taken after PAT imaging confirmed MB uptake in the SLN (vide
infra).
SPECT imaging showed localized signal from 125I-MB in the axillary region within 1 h after
injection (Figure 3). The high intensity regions at the injection site, in the forelimb and at the
location of the axillary lymph nodes were easily distinguished, allowing accurate mapping
of the lymph fields. Approximately 9% (17.7+/−0.48 µCi, n=3) of the injected dose was
detected in the axillary lymph node within 1 h after injection while almost no signal was
detected in the region of the contralateral lymph node (Figure 3). High uptake was
confirmed by planar scintigraphy and post-mortem optical imaging (vide infra).
We further validated that both PAT and SPECT signals originated from the same lymph
node. Since our PAT and SPECT/CT imaging systems are not co-localized in the same lab
area, we explored a multimodal imaging platform. In principle, 125I-MB can provide
photoacoustic, fluorescence, and gamma imaging signals. However, it was difficult to detect
MB fluorescence through the skin by planar reflectance optical imaging. After removing the
skin in the MB injection area, the lymph node and vessels were detected visually by dark
blue stains (Figure 4A). The lymph tracts leading to the lymph node can be seen as well.
Even with the exposed skin, only low fluorescence signal was detected in the forelimb and
in the lymphatic vasculature, but was particularly dim from the area of the lymph node. This
low nodal fluorescence could be attributed to the low fluorescence quantum yield of MB and
likely quenching within the highly stained lymph nodes. The strength of the PAT signal
suggests that much lower concentrations of MB can be used in future studies.
Unlike fluorescence imaging, planar gamma scintigraphy clearly showed high intensity from
the left paw, lymphatic vessel, and lymph node (Figure 4C) corresponding with the dark
blue color observed in Figure 4A. The animal was euthanized, and then the dissected lymph
nodes from the left axillary region were removed. After dissection, the first lymph node is
distinctly blue from dye accumulation while the following nodes are free of the dye (Figure
4B). Thus, the post-mortem photograph taken after PAT imaging confirmed MB uptake in
the SLN. Similarly, the ex-vivo planar scintigraphy confirmed that the first lymph node is
the source of the SPECT signal, demonstrating that 125I-MB could serve as a reliable
molecular imaging probe for in vivo validation of PAT in clinical trials.
Discussion
Central to current SLN mapping is the administration of two complementary detection
agents, 99mTc-labeled colloids and MB to guide SLN identification and biopsy. Although
the goal of the procedure is to localize the SLN, significant differences in the size, physical
and chemical properties of these two agents result in differential distributions and uptakes of
the agents in the lymph nodes. These differences are not problematic when used for SLN
detection and biopsy. However, validation of PAT for human use will benefit from a direct
comparison of the nascent PAT method with established SPECT. Although PAT has been
shown to image objects several centimeters in animal tissue, the optical properties of human
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tissue are different and it is important to demonstrate that PAT will not miss critical SLNs in
humans.
To facilitate this validation, we explored the use of a single imaging agent for both PAT and
SPECT. Previous studies have shown that MB can be radio-iodinated with different
radioisotopes of iodine for imaging cancer in humans and animals 18. These studies
demonstrated that the combination of radiotracer and MB increases the rate of correct SLN
detection. In particular, 125I-MB has been previously reported as an alternative to the
mixture of 99mTc colloid and MB for intra-operative guidance of SLN biopsy. A phase I/II
clinical trial was performed in which a handheld gamma detector was used to locate hotspots
followed by skin incision and excision of SLNs that were stained blue 19.
We prepared 125I-MB and used it in a different context from previously reported
applications. Here, MB served as a contrast agent for PAT, which relies on light absorption
by chromophores such as exogenous dyes or endogenous targets like hemoglobin. This
absorption process generates local thermal expansion of tissue that is captured as an acoustic
signal for PAT image reconstruction. By radiolabeling MB with 125I, it also yields SPECT
signals, thus providing a direct approach to validate the application of the nascent PAT for
lymph node mapping in humans. This is particularly important if PAT will be used as a
standalone noninvasive imaging modality in the surgical room. We used a small animal
model of lymph node mapping to explore the validity of the aforementioned strategy. Our
study showed that the multimodal optical-nuclear contrast agent can be used to confirm the
location of SLNs detected by noninvasive PAT in deep tissue. This strategy of validation is
effective for preclinical and clinical studies using PAT.
Mapping of the lymphatic vasculature and nodes by high resolution PAT for SLN biopsy
demonstrated great potential. Validation of this technique by SPECT/CT will improve
whole-field identification of lymph nodes draining the tumor area. The successful
demonstration of lymph node localization using the clinically compatible 125I-MB imaging
agent in small animals and the ability of PAT to interrogate deep tissue suggest that this
strategy will speed clinical translation of PAT for SLN biopsy.
Conclusion
SLN biopsy has become the standard of care for staging of many types of cancer. The nodal
status is an important prognostic indicator after diagnosis of cancer. PAT has demonstrated
great potential for non-invasive detection of SLN after injection of an optically absorbing
contrast agent. Validation of PAT for SLN biopsy is needed for clinical translation. The
multimodal imaging approach presented in this report is a good strategy for validation of
optical imaging techniques. This multimodal technique will be useful for validating the
signal location determined by non-invasive PAT using the hand-held device. SLN mapping
for subsequent fine needle aspirate, core needle biopsy or minimally invasive resection can
be achieved with high confidence. The next stage is to use the dual reporter imaging probe
in human studies, a process that will help validate the future role of PAT in breast cancer
staging.
Background
Identification of cancer cells in the lymph nodes surrounding a tumor is important in
establishing prognosis. Optical detection techniques such as fluorescence and
photoacoustic tomography (PAT) have been reported in preclinical studies for
noninvasive sentinel lymph node (SLN) mapping. A method for validation of these
techniques is needed for clinical trials.
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Translational Significance
We report the use of a multimodal optical-radionuclear probe to validate PAT in a
preclinical model. The approach will facilitate translation of PAT into the clinic through
comparison with clinically relevant SPECT. The high resolution PAT is sensitive and
accurate for SLN detection in cancer patients.
Abbreviations
PAT photoacoustic tomography
SLN sentinel lymph node
MB methylene blue
SPECT single-photon emission computed tomography
PET positron emission tomography
CT computed tomography; US = ultrasound
US ultrasound
IP intraperitneal
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FIGURE 1.
Structures of methylene blue and iodo-methylene blue 17 (top). Reversed phase radio-
chromatogram of 125I-iodo-methylene blue (bottom).
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FIGURE 2.
PAT imaging of lymph nodes after injection of MB. A) Control PAT image obtained before
MB injection. B) PAT image taken at 10 minutes post-injection. C) Overlaid PAT (pseudo
color) and US (gray scale) image. PAT, photoacoustic tomography; US, ultrasound imaging;
MB, methylene blue; and SLN, sentinel lymph node.
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FIGURE 3.
SPECT/CT projection images of rat acquired 1 h after subcutaneous injection of 125I-MB in
the left forepaw. * indicates location of injection and crosshairs indicate location of signal
from axillary lymph node. The red arrow indicates the contralateral lymph node in the
transverse view. The lymph node was detected about 3 mm below the surface of the skin,
correlating well with the PAT finding.
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FIGURE 4.
Post-mortem optical and planar scintigraphy of rat 2 h after subcutaneous injection of 125I-
MB in the left forepaw. A) The MB can be clearly seen as blue coloring in the forepaw near
the site of injection (*) and at the first lymph node after removal of overlying skin and hair.
The lymph tracts leading to the lymph node can be seen as well (arrows). B) Planar
scintigraphy corresponds with blue color with high intensity from the left paw and lymph
node. C) After dissection, the first lymph node is distinctly blue from dye accumulation
while the following nodes are free of the dye. D) Ex vivo scintigraphy confirmed that the
first lymph node was the source of the signal.
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